Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib DDI Study in Healthy Adults
NCT07223671Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of repotrectinib in non-small cell lung cancer (NSCLC) and solid tumor (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration at Day 17, Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time at Day 17 and 3 more. Started Dec 2025; status: completed.
02
Drugs
repotrectinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07223671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223671.